<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04489134</url>
  </required_header>
  <id_info>
    <org_study_id>35RC19_8877_DIPLOID</org_study_id>
    <nct_id>NCT04489134</nct_id>
  </id_info>
  <brief_title>P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release</brief_title>
  <acronym>DIPLOID</acronym>
  <official_title>P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tacrolimus is a drug administered orally available with different formulations: immediate&#xD;
      release (Prograf®), prolonged-release (Advagraf®) and an extended-release one named LCP-Tacro&#xD;
      (Envarsus®), formulated using the Melt-Dose process.&#xD;
&#xD;
      Tacrolimus is a lipophilic macrolide drug able to passive transmembrane diffusion. Its&#xD;
      bioavailability displays a large interindividual variability, from 9 to 43%. Indeed,&#xD;
      tacrolimus is a substrate of P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4). P-gp is&#xD;
      an efflux protein mainly located at the apex of the epithelia of the intestine, lymphocyte,&#xD;
      kidney and blood-brain barrier. P-gp therefore limits the intestinal resorption of tacrolimus&#xD;
      and also its diffusion into its target compartment (i.e the lymphocyte. The expression of&#xD;
      this protein is different throughout the digestive tract with maximum expression at the ileal&#xD;
      level. CYP3A4 is a coenzyme that is responsible of more than 90% of the metabolism of&#xD;
      tacrolimus, at the digestive and hepatic level. Both P-gp and CYP3A4 play a role in&#xD;
      tacrolimus absorption/diffusion process.&#xD;
&#xD;
      A new formulation of tacrolimus, LCP-Tacro, (Envarsus®) was approved in 2014. Its efficacy&#xD;
      was compared to Prograf® in two phase III de novo or switch Prograf® trials in kidney&#xD;
      transplantation.&#xD;
&#xD;
      With tacrolimus, there is a strong inter-individual pharmacokinetic variability which, to&#xD;
      date, has not been fully characterized. Variations in bioavailability may partly explain this&#xD;
      high variability. The different formulations are resorbed at distinct gastrointestinal sites&#xD;
      which could explain different absorptions between Prograf/Advagraf and LCP-Tacro forms.&#xD;
&#xD;
      These findings raise the question of the role of P-gp in explaining the difference in&#xD;
      bioavailability between formulations. The use of a P-gp inhibitor could therefore have a&#xD;
      different impact on exposure to different galenic formulations.&#xD;
&#xD;
      Verapamil is an inhibitor of P-gp and CYP 3A4, which is frequently prescribed and recommended&#xD;
      by FDA for drug-drug interaction studies aiming at evaluating P-gp substrates, used in&#xD;
      healthy volunteers at dosages up to 240 mg/D13-14. Otherwise, verapamil-tacrolimus&#xD;
      interaction has been characterized in vitro.&#xD;
&#xD;
      It has also been shown that inhibitory effect of verapamil at a single dose of 120 mg&#xD;
      administered one hour prior to the administration of a P-gp substrate exhibited an optimum&#xD;
      power of inhibition.&#xD;
&#xD;
      The safety of Advagraf® and Envarsus® administrations have already been subjected to several&#xD;
      phase I trials in healthy volunteers reinforcing the knowledge of their safety profile.&#xD;
&#xD;
      The aim of the study is to compare the interaction profile of Advagraf® and Envarsus® when&#xD;
      co-administered with verapamil in healthy subjects and to provide guidelines on tacrolimus&#xD;
      dosage adjustment in such cases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a pharmacokinetic, monocentric, prospective, randomized, crossover study with blind assessment (biologists performing tacrolimus dosages will be blind to the treatment received).</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>the biologists performing the tacrolimus assays will be blind to the treatment received</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>Between 0 and 24 hours</time_frame>
    <description>Change in area under the curve of tacrolimus blood concentrations between 0 and 24h.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Cmax Advagraf: 2-3 hours, Cmax Envarsus: 6-8 hours</time_frame>
    <description>Blood pharmacokinetic parameters: peak concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration</measure>
    <time_frame>24 hours</time_frame>
    <description>Blood pharmacokinetic parameters: trough concentration (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Blood pharmacokinetic parameters: apparent clearance (Cl/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Blood pharmacokinetic parameters: half-life (T1/2)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Intracellular pharmacokinetic parameters: AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Cmax Advagraf: 2-3 hours, Cmax Envarsus: 6-8 hours</time_frame>
    <description>Intracellular pharmacokinetic parameters: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin</measure>
    <time_frame>24 hours</time_frame>
    <description>Intracellular pharmacokinetic parameters:Cmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CI/F</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Intracellular pharmacokinetic parameters: Cl/F</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Intracellular pharmacokinetic parameters:T1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABCB1 genotypes</measure>
    <time_frame>Day 0</time_frame>
    <description>ABCB1 genotypes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Others genotypes</measure>
    <time_frame>Day 0</time_frame>
    <description>Other genotypes of interest coding for metabolism (CYP3A4, CYP3A5…) or drug transport (CNT3…).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>A D B C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period n°01: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro Period n°03:Administration of a 2 mg dose of LCP-tacro Period n°04:Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B A C D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period n°01: Administration of a 2 mg dose of LCP-tacro Period n°02:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C B D A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period n°01: Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a 2 mg dose of LCP-tacro Period n°03:Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro Period n°04:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D C A B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period n°01:Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro Period n°02:Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a 2 mg dose of LCP-tacro</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A</intervention_name>
    <description>Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)</description>
    <arm_group_label>A D B C</arm_group_label>
    <arm_group_label>B A C D</arm_group_label>
    <arm_group_label>C B D A</arm_group_label>
    <arm_group_label>D C A B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B</intervention_name>
    <description>Administration of a 2 mg dose of LCP-tacro</description>
    <arm_group_label>A D B C</arm_group_label>
    <arm_group_label>B A C D</arm_group_label>
    <arm_group_label>C B D A</arm_group_label>
    <arm_group_label>D C A B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treament C</intervention_name>
    <description>Administration of a single 120 mg dose of immediate-release verapamil and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)</description>
    <arm_group_label>A D B C</arm_group_label>
    <arm_group_label>B A C D</arm_group_label>
    <arm_group_label>C B D A</arm_group_label>
    <arm_group_label>D C A B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment D</intervention_name>
    <description>Administration of a single 120 mg dose of immediate release verapamil and a 2 mg dose of LCP-tacro</description>
    <arm_group_label>A D B C</arm_group_label>
    <arm_group_label>B A C D</arm_group_label>
    <arm_group_label>C B D A</arm_group_label>
    <arm_group_label>D C A B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pharmacocinetik</intervention_name>
    <description>Nine sampling points of 7 ml each will be taken on the first day at the CIC UIC and the last sampling point will be carried out at 24 hours from the administration the following morning.</description>
    <arm_group_label>A D B C</arm_group_label>
    <arm_group_label>B A C D</arm_group_label>
    <arm_group_label>C B D A</arm_group_label>
    <arm_group_label>D C A B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic</intervention_name>
    <description>A genetic analysis to determine your characteristics for enzymes in your metabolism as well as transport proteins will be carried out. An additional 7 ml blood tube will be drawn for this purpose during the first period.</description>
    <arm_group_label>A D B C</arm_group_label>
    <arm_group_label>B A C D</arm_group_label>
    <arm_group_label>C B D A</arm_group_label>
    <arm_group_label>D C A B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Selection visit:</intervention_name>
    <description>During this visit, it will be asked to sign the following consent and it will be carried out:&#xD;
a clinical examination (questioning and physical examination with measurement of height and weight);&#xD;
a blood test (18 mL);&#xD;
a blood pregnancy test if you are a woman;&#xD;
a cardiac assessment (electrocardiogram).&#xD;
These results should be normal.</description>
    <arm_group_label>A D B C</arm_group_label>
    <arm_group_label>B A C D</arm_group_label>
    <arm_group_label>C B D A</arm_group_label>
    <arm_group_label>D C A B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults (&gt; 18 years)&#xD;
&#xD;
          -  Non smokers (for at least 6 months)&#xD;
&#xD;
          -  Biological parameters within normal range (blood count, urea, creatinine, AST, ALT,&#xD;
             GGT, bilirubine)&#xD;
&#xD;
          -  BMI within 18 and 25&#xD;
&#xD;
          -  Vvaccinated against Covid 19&#xD;
&#xD;
          -  Negative urinary and plasma pregnancy test&#xD;
&#xD;
          -  Having effective contraception for the duration of the study and for 10 days after the&#xD;
             last administration of the study treatment (for women and men of childbearing&#xD;
             potential)&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  participation to another study with incompatible procedure regarding the French law on&#xD;
             research&#xD;
&#xD;
          -  Treatment with a drug drug interaction with tacrolimus&#xD;
&#xD;
          -  Cardiac rhythm at rest below 50 bpm&#xD;
&#xD;
          -  Cardiac issue detected on electrocardiogram&#xD;
&#xD;
          -  Cancer or history of cancer&#xD;
&#xD;
          -  Chronic infection or history of chronic infection&#xD;
&#xD;
          -  Diabetes or history of diabetes&#xD;
&#xD;
          -  Hypertension or history of hypertension&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Deprived of liberty (curatorship, guardianship or incarcerate)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie LE NAOU</last_name>
    <phone>299282555</phone>
    <phone_ext>33</phone_ext>
    <email>marie.lenaou@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruno Laviolle</last_name>
    <email>bruno.laviolle@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35055</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno Laviolle</last_name>
      <email>bruno.laviolle@chu-rennes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Florian Lemaitre</last_name>
      <email>florian.lemaitre@chu-rennes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Fabrice Lainé</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno Laviolle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

